{"id":68915,"date":"2026-06-25T23:58:52","date_gmt":"2026-06-25T15:58:52","guid":{"rendered":"https:\/\/flcube.com\/?p=68915"},"modified":"2026-06-25T23:58:54","modified_gmt":"2026-06-25T15:58:54","slug":"mabwell-bioscience-secures-nmpa-approval-for-9mw5211-clinical-trial-in-multiple-sclerosis-expanding-autoimmune-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68915","title":{"rendered":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Mabwell (Shanghai) Bioscience Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved the <strong>clinical trial application<\/strong> for <strong>9MW5211 injection<\/strong> for the treatment of <strong>multiple sclerosis (MS)<\/strong>. This marks the second autoimmune indication for the innovative antibody, which previously received clinical trial approvals in both <strong>China and the United States<\/strong> for <strong>inflammatory bowel disease (IBD)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial application approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>9MW5211 injection (highly specific depleting antibody)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Multiple sclerosis (MS)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>25 Jun 2026<\/td><\/tr><tr><td><strong>Previous Approvals<\/strong><\/td><td>IBD trials approved in China and US<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Highly specific depleting innovative antibody (9MW5211)<\/li>\n\n\n\n<li><strong>Target:<\/strong> Surface protein specifically expressed on pathogenic immune cells<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Precision intervention targeting key pathological mechanisms mediated by aberrant immune cells in autoimmune diseases<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Selectively recognizes and depletes pathogenic immune cells with abnormal activation, effectively blocking the immune cascade response<\/li>\n\n\n\n<li><strong>Selectivity Advantage:<\/strong> Excellent target selectivity achieves efficient blockade while significantly reducing risk of non-specific binding<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Profound depletion of pathogenic cells with high target protein expression, alleviating disease progression and improving clinical symptoms<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-scientific-rationale\" class=\"wp-block-heading\">Scientific Rationale<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Multiple sclerosis and inflammatory bowel disease share common pathological features characterized by <strong>abnormal activation and tissue infiltration of immune cells<\/strong>, which serve as core drivers of disease onset and progression. The molecular target of 9MW5211 functions as an <strong>important biomarker<\/strong> for abnormal immune cell activation, making it an ideal therapeutic target for precision intervention.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By focusing on pathogenic immune cells rather than broad immunosuppression, 9MW5211 represents a <strong>next-generation approach<\/strong> to autoimmune disease treatment that aims to preserve normal immune function while specifically eliminating disease-causing cells.<\/p>\n\n\n\n<h2 id=\"h-strategic-pipeline-expansion\" class=\"wp-block-heading\">Strategic Pipeline Expansion<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Indication Strategy:<\/strong> Simultaneous development in MS and IBD demonstrates platform potential across multiple autoimmune conditions<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> US clinical trial approval for IBD positions Mabwell for international expansion<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> High target selectivity addresses limitations of existing broad-spectrum immunosuppressants<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> MS affects approximately 2.8 million people globally, with growing prevalence in Asia-Pacific regions<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Successful advancement of 9MW5211 validates Mabwell&#8217;s proprietary antibody discovery and engineering capabilities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of 9MW5211. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics in the autoimmune therapeutics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688062_20260625_RBEP.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688062_20260625_RBEP.\"><\/object><a id=\"wp-block-file--media-e48d2da5-c0db-4418-9a55-dd60a58ce5ef\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688062_20260625_RBEP.pdf\">688062_20260625_RBEP<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688062_20260625_RBEP.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e48d2da5-c0db-4418-9a55-dd60a58ce5ef\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,118,1129],"class_list":["post-68915","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-mabwell-bioscience","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China&#039;s National Medical Products Administration (NMPA) has approved the clinical trial application for 9MW5211 injection for the treatment of multiple sclerosis (MS). This marks the second autoimmune indication for the innovative antibody, which previously received clinical trial approvals in both China and the United States for inflammatory bowel disease (IBD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68915\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline\" \/>\n<meta property=\"og:description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China&#039;s National Medical Products Administration (NMPA) has approved the clinical trial application for 9MW5211 injection for the treatment of multiple sclerosis (MS). This marks the second autoimmune indication for the innovative antibody, which previously received clinical trial approvals in both China and the United States for inflammatory bowel disease (IBD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68915\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-25T15:58:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-25T15:58:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68915#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68915\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline\",\"datePublished\":\"2026-06-25T15:58:52+00:00\",\"dateModified\":\"2026-06-25T15:58:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68915\"},\"wordCount\":402,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Mabwell Bioscience\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68915#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68915\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68915\",\"name\":\"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-25T15:58:52+00:00\",\"dateModified\":\"2026-06-25T15:58:54+00:00\",\"description\":\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application for 9MW5211 injection for the treatment of multiple sclerosis (MS). This marks the second autoimmune indication for the innovative antibody, which previously received clinical trial approvals in both China and the United States for inflammatory bowel disease (IBD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68915#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68915\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68915#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application for 9MW5211 injection for the treatment of multiple sclerosis (MS). This marks the second autoimmune indication for the innovative antibody, which previously received clinical trial approvals in both China and the United States for inflammatory bowel disease (IBD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68915","og_locale":"en_US","og_type":"article","og_title":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline","og_description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application for 9MW5211 injection for the treatment of multiple sclerosis (MS). This marks the second autoimmune indication for the innovative antibody, which previously received clinical trial approvals in both China and the United States for inflammatory bowel disease (IBD).","og_url":"https:\/\/flcube.com\/?p=68915","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-25T15:58:52+00:00","article_modified_time":"2026-06-25T15:58:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68915#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68915"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline","datePublished":"2026-06-25T15:58:52+00:00","dateModified":"2026-06-25T15:58:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68915"},"wordCount":402,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Mabwell Bioscience","SHA: 688062"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68915#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68915","url":"https:\/\/flcube.com\/?p=68915","name":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-25T15:58:52+00:00","dateModified":"2026-06-25T15:58:54+00:00","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application for 9MW5211 injection for the treatment of multiple sclerosis (MS). This marks the second autoimmune indication for the innovative antibody, which previously received clinical trial approvals in both China and the United States for inflammatory bowel disease (IBD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68915#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68915"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68915#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis \u2013 Expanding Autoimmune Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68915"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68915\/revisions"}],"predecessor-version":[{"id":68920,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68915\/revisions\/68920"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}